Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)

A Bhimraj, RL Morgan, AH Shumaker… - Clinical Infectious …, 2020 - academic.oup.com
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

Outpatient treatment of confirmed COVID-19: a living, rapid review for the American College of Physicians

I Sommer, A Dobrescu, D Ledinger, I Moser… - Annals of internal …, 2023 - acpjournals.org
An updated version of this article was published on 19 September 2023. This article has
been corrected. The original version of the article and supplement (PDF) is appended to this …

Outpatient randomized controlled trials to reduce COVID‐19 hospitalization: Systematic review and meta‐analysis

DJ Sullivan, D Focosi, DF Hanley… - Journal of Medical …, 2023 - Wiley Online Library
This COVID‐19 outpatient randomized controlled trials (RCTs) systematic review compares
hospitalization outcomes amongst four treatment classes over pandemic period, geography …

Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities

R Kumar, Ö Aktay-Cetin, V Craddock… - PLoS …, 2023 - journals.plos.org
The Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) and its sublineages pose a new challenge to healthcare …

[HTML][HTML] Efficacy of ivermectin, chloroquine/hydroxychloroquine, and azithromycin in managing COVID-19: A systematic review of phase III clinical trials

NMS Sansone, MN Boschiero, FAL Marson - Biomedicines, 2024 - mdpi.com
Background: During the coronavirus disease (COVID)-19 pandemic several drugs were
used to manage the patients mainly those with a severe phenotype. Potential drugs were …

COVID-19 therapeutics

D Focosi, M Franchini, F Maggi… - Clinical Microbiology …, 2024 - Am Soc Microbiol
Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …

[HTML][HTML] Outpatient regimens to reduce COVID-19 hospitalisations: a systematic review and meta-analysis of randomized controlled trials

DJ Sullivan, D Focosi, DF Hanley, M Cruciani… - MedRxiv, 2023 - ncbi.nlm.nih.gov
Background During pandemics, early outpatient treatments reduce the health system
burden. Randomized controlled trials (RCTs) in COVID-19 outpatients have tested …

The effect of ACE inhibitors and ARBs on outcomes in hospitalized patients with COVID-19

N Najafi, A Davoudi, H Izadyar, A Alishahi… - Irish Journal of Medical …, 2023 - Springer
Background Contradictory opinions exist regarding the use of angiotensin-converting
enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with …

Ivermectin affects neutrophil-induced inflammation through inhibition of hydroxylysine but stimulation of cathepsin G and phenylalanine secretion

SI Galkina, EA Golenkina, MV Serebryakova… - Biomedicines, 2022 - mdpi.com
The invasion and integrin-dependent adhesion of neutrophils to lung tissues and their
secretion lead to the development of pneumonia in various pulmonary pathologies …

[HTML][HTML] Perspective: repurposed drugs for COVID-19

K Na-Bangchang, S Porasuphatana… - Archives of Medical …, 2022 - ncbi.nlm.nih.gov
Methods Research articles and guidelines related to therapy of COVID-19 were searched
from the PubMed database. Results Only remdesivir and tocilizumab are medicines that …